Alteration by prolactin of surface charge and membrane fluidity of rat 13762 mammary ascites tumor cells.
Intraperitoneal injection of ovine prolactin (100 micrograms/d) in Fischer 344 rats bearing transplantable 13762 mammary ascites tumor (MAT) cells modifies the surface charge density and membrane fluidity of the tumor cells. In each of five experiments the mean electrophoretic mobility (epm) of MAT cells taken from prolactin-treated rats was significantly lower than that of cells from nonhormone-treated controls. Prolactin concentrations were increased in vivo by (a) direct intraperitoneal injection of ovine prolactin; (b) subcutaneous implantation of diethylstilbestrol-containing silastic capsules to produce pituitary prolactin secreting tumors; or (c) a single subcutaneous injection of polyestradiol phosphate, a long-acting estrogen. In an effort to establish that the prolactin effect was a direct one, two in vivo protocols were used: (a) MAT cells were coincubated with anterior pituitary halves obtained from nontumor-bearing littermates; or (b) rat or ovine prolactin was added to serum-free culture media containing MAT cells. In both protocols, the epm of the prolactin-treated cells was significantly lower. The isoelectric focusing pH of whole cells was increased by prolactin treatment from 4.93 to 5.12, consistent with a reduction in the number of surface carboxyl groups. The fluidity of membranes of treated cells was drastically increased, as measured by spin-label probe rotation rates. These combined results imply that the hormone exerts its effect by stimulating events in the cell that lead to a reduction of the average density of carboxylic acid residues on the tumor cell surface.
D000818:Animals; D002478:Cells, Cultured; D004054:Diethylstilbestrol; D004343:Drug Implants; D004578:Electron Spin Resonance Spectroscopy; D004594:Electrophysiology; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D007525:Isoelectric Focusing; D008325:Mammary Neoplasms, Experimental / Q000503:physiopathology*; D008560:Membrane Fluidity / Q000187:drug effects*; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000139:chemically induced / Q000378:metabolism; D011388:Prolactin / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D013499:Surface Properties
D004343:Drug Implants; D004958:Estradiol; D004054:Diethylstilbestrol; D011388:Prolactin; C008958:polyestradiol phosphate